Our innovative technology becomes available for patients
February 7, 2017METAFORA and collaborators publishes a paper in Annals of Neurology
June 19, 2017The METAglut1 test developed by METAFORA to diagnose the GLUT1 deficiency syndrome through a simple blood sample has been CE marked starting February 2017. This test is fully automated all the way through data analysis obtained by flow cytometry. Thanks to innovative algorithms the metabolic defect can be detected in patients in a fast and secure way.
METAglut1 therefore becomes the first ever totally automated quantitative cytometry test to be CE marked. Meant for routine medical use the test can be prescribed for patients with epileptic seizures, movement disorders and learning disabilities who are frequently exposed to long medical wandering.